LIVE PULSE
3.9 Anthropic CEO Amodei calls for slower AI development and shared safety rules — 11 src2.1 Agility Robotics unveils Digit 5 humanoid for warehouses and factories — 2 src2.0 Apple ships rebuilt Siri with Google Gemini, but not in the EU — 2 src1.7 Siri AI in macOS 27 Golden Gate: FAQ, Germany availability, privacy questions — 2 src1.4 Sam Altman says OpenAI will not go public in 2026, citing AI safety concerns — 5 src1.1 OpenAI contractors review real ChatGPT conversations to rate responses, report says — 2 src1.1 Anthropic data retention policy prompts firms to limit Claude use for sensitive work — 1 src1.1 Study examines issue bias in LLMs used as writing assistants before Swedish 2026 election — 1 src1.1 Study Audits Misalignment in Multi-Modal World Models — 1 src1.1 Retrieval-Grounded Reasoning Approach Proposed for Universal Multimodal Embeddings — 1 src3.9 Anthropic CEO Amodei calls for slower AI development and shared safety rules — 11 src2.1 Agility Robotics unveils Digit 5 humanoid for warehouses and factories — 2 src2.0 Apple ships rebuilt Siri with Google Gemini, but not in the EU — 2 src1.7 Siri AI in macOS 27 Golden Gate: FAQ, Germany availability, privacy questions — 2 src1.4 Sam Altman says OpenAI will not go public in 2026, citing AI safety concerns — 5 src1.1 OpenAI contractors review real ChatGPT conversations to rate responses, report says — 2 src1.1 Anthropic data retention policy prompts firms to limit Claude use for sensitive work — 1 src1.1 Study examines issue bias in LLMs used as writing assistants before Swedish 2026 election — 1 src1.1 Study Audits Misalignment in Multi-Modal World Models — 1 src1.1 Retrieval-Grounded Reasoning Approach Proposed for Universal Multimodal Embeddings — 1 src
HEATPULSEAI MAGAZINES
FLIP · FOLLOW · SAVE
Log inSign up

clinical-trial-redesign

topic1 events
papersTODAY 04:00 UTC

ClinicalReTrial: Self-Evolving Agents for Clinical Trial Redesign

A new arXiv paper introduces ClinicalReTrial, a system that uses self-evolving AI agents to revise clinical trial protocols. The work targets the high cost and complexity of drug development, where trial designs are written as lengthy natural-language documents that are difficult to analyze manually. The authors frame agent-based redesign as an alternative to conventional manual protocol review.

agents/research/healthcare/clinical-trials